Kura Oncology, Inc. (NASDAQ:KURA) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET

Company Participants

Pete De Spain - Head of Investor Relations

Troy Wilson - President & Chief Executive Officer

Tom Doyle - Senior Vice President of Finance & Accounting

Conference Call Participants

Jason Zemansky - Bank of America

Peter Lawson - Barclays

Roger Song - Jefferies

Li Watsek - Cantor Fitzgerald

Jeet Mukherjee - BTIG

Phil Nadeau - TD Cowen

Brad Canino - Stifel

Operator

Good afternoon, ladies and gentlemen, and welcome to the Third Quarter 2023 Kura Oncology Inc. Earnings Conference Call. At this time, all lines are in listen-only mode. Following the presentation, we will conduct a question-and-answer session. [Operator Instructions] This call is being recorded on Thursday, November 2, 2023.

I would now like to turn over the call to Pete De Spain, Head of Investor Relations. Please go ahead.

Pete De Spain

Thank you, Lester. Good afternoon, and welcome to Kura Oncology's third quarter 2023 conference call. Joining me on the call are, Dr. Troy Wilson, our President and Chief Executive Officer; and Tom Doyle, our Senior Vice President of Finance and Accounting.

Before I turn the call over to Dr. Wilson, I'd like to remind you that today's call will include forward-looking statements based on current expectations. Such statements represent management's judgment as of today and may involve risks and uncertainties that could cause actual results to differ materially from expected results. Please refer to Kura's filings with the SEC, which are available from the SEC or on the Kura Oncology website for information concerning risk factors that could affect the company.

With that, I'll now turn the call over to Troy.

Troy Wilson

Thank you, Pete, and thank you all for joining us. Let's jump right in. We believe our lead drug candidate ziftomenib is well positioned for market leadership with multibillion-dollar global revenue potential in acute leukemias and beyond. Our conviction is supported by a growing body of clinical data, as a monotherapy and more recently in combination with standards of care. A rapid pace of enrollment in our ongoing studies driven by strong clinical data and robust enthusiasm among investigators and patients, and a best-in-class safety and tolerability profile that we believe will enable ziftomenib to become a backbone of therapy across the continuum of care for AML patients.

Ziftomenib is a once-daily oral drug candidate that targets the menin-KMT2A protein-protein interaction and has potential to address all patients for whom the menin-KMT2A pathway is a disease driver, representing up to 50% of patients with AML. In our Phase 1 trial, ziftomenib demonstrated an impressive 35% CR rate and 45% overall response rate in 20 patients with NPM1-mutant AML treated at the recommended Phase 2 dose of 600 milligrams.